Updating the beers criteria for potentially Freecams chilenas
Owens, MD, Christopher Tessier, MD Jennifer Bertsch, Margaret Hoogland (Medical Librarian), Heddy Hubbard, Ph D, MPH, RN, FAAN, Suzanne Pope, MBA, Stephanie Stinchcomb, CPC, CCS-P, ACS-UR, Cecelia Shertz Wall (Medical Writer), Marni Yoffe, MA (Methodologist), Kathleen Zwarick, Ph D, CAE Introduction: Medication-related problems are common but may be preventable outcomes of prescribing choices.
Apart from the newer overactive bladder (OAB) medication mirabegron (which was launched after the systematic review was completed for the 2012 Beers Criteria revision), there are currently no other oral pharmaceutical substitutes for the antimuscarinics.
We also identified that the Healthcare Effectiveness Data and Information Set (HEDIS®) high-risk medications (HRM) list of PIMs has been implemented as a negative quality indicator, even though this was not an original purpose of the Beers Criteria.
In other words, denial of coverage and/or requirements for preauthorization are being made using the Beers Criteria as justification by third-party payers and other entities.
Methods: A literature review was performed targeting publications between 20 on the topics of the Beers Criteria, PIMs, and specific urologic medications included in the current version of the Beers Criteria.
An expert panel was convened to evaluate this information and create this white paper with the purpose of educating the urologic community on these issues.